Histopathologic diagnosis of brain metastases: current trends in management and future considerations
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Histopathologic diagnosis of brain metastases: current trends in management and future considerations
Authors
Keywords
Brain metastases, Anatomopathology, Immunohistochemistry, Molecular biology, Markers, Targeted therapies
Journal
Brain Tumor Pathology
Volume 34, Issue 1, Pages 8-19
Publisher
Springer Nature
Online
2016-11-23
DOI
10.1007/s10014-016-0275-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.
- (2017) S. Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Colon Cancer, Version 3.2014
- (2017) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion–Positive Metastatic Non–Small-Cell Lung Cancer
- (2016) Gerald S. Falchook et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic Immunotherapy for the Treatment of Brain Metastases
- (2016) Justine V. Cohen et al. Frontiers in Oncology
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
- (2015) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
- (2015) Keith M. Kerr et al. Journal of Thoracic Oncology
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of RAS family members confers resistance to ROS1 targeting drugs
- (2015) Marilisa Cargnelutti et al. Oncotarget
- Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms
- (2015) George J. Burghel et al. Biomed Research International
- Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases
- (2015) Anna S Berghoff et al. OncoImmunology
- Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
- (2014) S. M. Swain et al. ANNALS OF ONCOLOGY
- BRAF alterations in brain tumours
- (2014) Anna Sophie Berghoff et al. CURRENT OPINION IN NEUROLOGY
- Napsin A is a useful marker for metastatic adenocarcinomas of pulmonary origin
- (2014) Moon-Young Kim et al. HISTOPATHOLOGY
- ROS1 translocations and amplifications in lung cancer brain metastases
- (2014) Matthias Preusser et al. JOURNAL OF NEURO-ONCOLOGY
- Discoidin Domain Receptor 2 Signaling Networks and Therapy in Lung Cancer
- (2014) Leo S. Payne et al. Journal of Thoracic Oncology
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape
- (2014) Huiyong Sun et al. PLoS Computational Biology
- Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification byKRASMutations in Advanced Colorectal Cancer
- (2013) Issa J. Dahabreh et al. ANNALS OF INTERNAL MEDICINE
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
- (2013) D. McDermott et al. ANNALS OF ONCOLOGY
- FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
- (2013) F. Loupakis et al. EUROPEAN JOURNAL OF CANCER
- Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update
- (2013) Nelson G. Ordóñez HUMAN PATHOLOGY
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib
- (2013) Oliver Gautschi et al. Journal of Thoracic Oncology
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer
- (2013) Matthias Preusser et al. LUNG CANCER
- Case 16-2013: A Girl with Irritability, Hypersomnia, and Somatic Symptoms
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
- (2013) Kurtis D. Davies et al. PLoS One
- Challenging resistance mechanisms to therapies for metastatic melanoma
- (2013) Lucio Tentori et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- In Search of the Ideal Immunopanel to Distinguish Metastatic Mammary Carcinoma From Primary Lung Carcinoma
- (2013) Kathy R. Kawaguchi et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Brain metastases: pathobiology and emerging targeted therapies
- (2012) Matthias Preusser et al. ACTA NEUROPATHOLOGICA
- Characterization of the inflammatory response to solid cancer metastases in the human brain
- (2012) Anna Sophie Berghoff et al. CLINICAL & EXPERIMENTAL METASTASIS
- A Molecular Signature for Oncogenic BRAF in Human Colon Cancer Cells is Revealed by Microarray Analysis
- (2012) T. Joyce et al. CURRENT CANCER DRUG TARGETS
- Brain metastases as the first symptom of lung cancer: a clinical study from an Asian medical center
- (2012) Jia Jin et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR mutation status in brain metastases of non-small cell lung carcinoma
- (2012) Fanny Burel-Vandenbos et al. JOURNAL OF NEURO-ONCOLOGY
- Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer
- (2012) Leow Pay Chin et al. Journal of Thoracic Oncology
- Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer
- (2012) Andrew J. Weickhardt et al. Journal of Thoracic Oncology
- Cancer classification using the Immunoscore: a worldwide task force
- (2012) Jérôme Galon et al. Journal of Translational Medicine
- The immune score as a new possible approach for the classification of cancer
- (2012) Jérôme Galon et al. Journal of Translational Medicine
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
- (2011) David Capper et al. ACTA NEUROPATHOLOGICA
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies
- (2011) Eitan Amir et al. CANCER TREATMENT REVIEWS
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
- (2011) A. M. Brufsky et al. CLINICAL CANCER RESEARCH
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- (2011) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction
- (2011) Bernhard Mlecnik et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
- (2011) Amit Dutt et al. PLoS One
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
- (2010) D. R. Camidge et al. CLINICAL CANCER RESEARCH
- High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
- (2010) Jennifer L. Clarke et al. JOURNAL OF NEURO-ONCOLOGY
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
- (2010) Ryoichi Onozato et al. Journal of Thoracic Oncology
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene
- (2009) Tsuyoshi Takahashi et al. ANNALS OF SURGICAL ONCOLOGY
- TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS
- (2009) Daisy Wing-Sze Wong et al. CANCER
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
- (2009) N. U. Lin et al. CLINICAL CANCER RESEARCH
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Defining prognosis for women with breast cancer and CNS metastases by HER2 status
- (2008) S. Dawood et al. ANNALS OF ONCOLOGY
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- (2008) David Cameron et al. BREAST CANCER RESEARCH AND TREATMENT
- KIT Gene Mutations and Copy Number in Melanoma Subtypes
- (2008) C. Beadling et al. CLINICAL CANCER RESEARCH
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- (2008) J. P. Koivunen et al. CLINICAL CANCER RESEARCH
- Major Response to Imatinib Mesylate in KIT-Mutated Melanoma
- (2008) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Central Nervous System Metastases in HER-2-Overexpressing Metastatic Breast Cancer: A Treatment Challenge
- (2008) H.-J. Stemmler et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now